Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto's thyroiditis by Gasbarri, A et al.
Detection and molecular characterisation of thyroid cancer
precursor lesions in a specific subset of Hashimoto’s thyroiditis
A Gasbarri
1,6, S Sciacchitano
2,6, A Marasco
1, M Papotti
3, A Di Napoli
1, A Marzullo
1, P Yushkov
4, L Ruco
1 and
A Bartolazzi*,1,5
1Department of Pathology, St’ Andrea Hospital, University La Sapienza, via di Grottarossa 1035, 00189 Rome, Italy;
2Department of Endocrinology,
University La Sapienza and St Peter Hospital Research Center, Associazione Fatebenefratelli for Research, via Cassia 600, 00189 Rome, Italy;
3Department of Biomedical Sciences and Human Oncology, University of Turin and St Luigi Hospital, Regione Gonzole 10, 10043 Orbassano, Turin, Italy;
4Department of Pathomorphology, Head Research Center for Endocrinology, Dmitry Ulyanov str. 11, 117036 Moscow, Russia;
5Department of Oncology-
Pathology, Cellular and Molecular Tumor Pathology, CCK R8:04, S-17176, Karolinska Hospital, Stockholm, Sweden
Hashimoto’s thyroiditis (HT) represents the most common cause of hypothyroidism and nonendemic goiter, but its clinical and
pathological heterogeneity opens the question if this disease should be more properly considered as a spectrum of different thyroid
conditions rather than as a single nosological entity. In this study, we analysed 133 cases of HT for the expression of galectin-3, a lectin
molecule involved in malignant transformation, apoptosis and cell cycle control. An unexpected expression of galectin-3 was
demonstrated in a subset of HT together with the presence of HBME-1, c-met and cyclin-D1 that are also involved in malignant
transformation and deregulated cell growth. Furthermore, a loss of allelic heterozygosity in a specific cancer-related chromosomal
region was demonstrated in some HT harbouring galectin-3-positive follicular cells, by using laser capture microdissection. On the
basis of the morphological and molecular findings we identified four subsets of HT: (a) HT with classic features of chronic
autoimmune thyroiditis; (b) HT associated to hyperplastic/adenomatous lesions; (c) HT harbouring thyroid cancer precursors; (d) HT
associated to unequivocal thyroid microcarcinomas. Our findings provide a well-substantiated morphological and molecular
demonstration that HT may include a spectrum of different thyroid conditions ranging from chronic autoimmune thyroiditis to
thyroiditis triggered by specific immune-response to cancer-related antigens.
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Hashimoto’s thyroiditis (HT) represents the most common cause
of hypothyroidism and nonendemic goiter. This pathological
entity was first described by Hashimoto in 1912 who reported four
patients with goiter in whom the histology of the thyroid gland was
characterised by diffuse lymphocyte infiltration, atrophy of
follicular cells, presence of eosinophilic granular thyrocytes (also
worded oncocytic cells or Hurtle’s cells) and fibrosis (Hashimoto,
1912). Over 40 years later, presence of autoantibodies was
discovered in patients with this disorder and HT was finally
categorised as a chronic autoimmune thyroiditis (Roitt et al, 1956).
The hallmark of autoimmune thyroiditis is the presence of
thyroid-specific autoantibodies in the serum, in particular anti-
thyroglobulin antibodies (TG), anti-thyroperoxidase (TPO) anti-
bodies and less frequently anti-TSH receptor antibodies, together
with a variable degree of thyroid dysfunction.
Patients affected by HT are generally referred for hypothyroid-
ism or for the presence of a nodular goiter characterised by its
firmness and irregular surface. Fine-needle aspiration biopsy
(FNA) reveals presence of lymphocytes and plasma cells infiltra-
tion, intermingled with eosinophilic granular thyrocytes.
These features, when coexisting with the presence of anti-TPO
antibodies, are considered diagnostic in most of the cases.
However, it is well known that patients with HT show a rather
wide spectrum of clinical and laboratory presentation. The
presence of significant serum levels of thyroid-specific autoanti-
bodies, in fact, is not the rule. Furthermore, occurrence of
glandular fibrosis and destruction of follicular epithelial cells are of
variable intensity and evolution (Dayan and Daniels, 1996). It is
noteworthy that only some Hashimoto’s goiters become atrophic
over the years. Thyroid fibrosis with dense infiltrate of plasma cells
represents the final evolution of these cases, but in the majority of
HTs, little histological progression has been observed in patients
undergoing a second biopsy up to 20 years after the first (Vickery
and Hamblin, 1961; Hayashi et al, 1985).
Here we present a morphological and molecular analysis of 133
histologically and clinically proven HTs showing a variable degree
of inflammation, oncocytic changes, fibrosis and glandular
atrophy, which are considered the histological hallmarks of this
disease.
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yMolecular and immunohistochemical studies directed to detect
specific gene profiles and related proteins in thyroid cancer have
been extensively reported in literature (Bartolazzi et al, 2001;
Huang et al, 2001; Ruco et al, 2001; Wreesmann et al, 2002).
Experimental data, mostly arising from the molecular analysis of
papillary thyroid carcinoma (PTC), contributed to identify a panel
of genes overexpressed in thyroid malignancy. Among these genes,
FN-1 (fibronectin-1), KRT-19 (keratin-19) and MET (hepatocyte
growth factor receptor) gene have been found consistently
overexpressed in PTC (Huang et al, 2001).
Overexpression of c-met protein has been reported
as a distinguishing feature of almost every case of well-
differentiated PTC, but interestingly a moderate expression of this
molecule was observed in peritumoral non-neoplastic follicles as
well as in some HTs (Ruco et al, 2001). Research in this field has
recently been focused on LGALS3 gene that codes for the b-
galactosil binding protein called galectin-3. This lectin molecule,
which is expressed in the vast majority of PTC, as well as in
follicular carcinoma, is directly involved in transformation of
follicular thyroid cells and in regulation of apoptosis (Bartolazzi
et al, 2001; Huang et al, 2001; Takenaka et al, 2003; Yang and Liu,
2003).
For its pattern of expression in thyroid cancer, galectin-3 has
recently been proposed as diagnostic marker of malignant
transformed thyrocytes (Bartolazzi et al, 2001).
In a subset of HTs assessed here, superimposed alterations of
follicular thyroid cells, ranging from focal cytoarchitectural atypia
to microcarcinoma were morphologically identified. Interestingly,
the vast majority of these lesions expressed galectin-3.
These findings raise the question if some HTs may be triggered
by specific immunoresponse to transformed thyrocytes.
Detection of both galectin-3-positive atypical areas and micro-
carcinomas, in a subset of HTs, supports the hypothesis that
precursor lesions of thyroid cancer may be present in these thyroid
conditions. To date, the diagnosis of HT has been mostly based on
clinical, immunological and histomorphological criteria, but it
seems that this conventional diagnostic approach only shows ‘one
side of the moon’.
MATERIALS AND METHODS
Histological samples and HT subclassification
A total of 133 cases of clinically and pathologically defined
HTs, collected from different Institutions, were tentatively
subclassified by using the following morphological criteria: (i)
HTs with classical features of chronic autoimmune thyroiditis: in
this group fall those cases of HT, in which a diffuse lymphocyte
infiltrate, sometimes organized in nodules or follicles, was
associated to oncocytic changes and to a variable degree of
fibrosis and atrophy of thyroid parenchyma; (ii) HTs with
coexistence of benign proliferating thyroid lesions: this cluster
included HTs associated to hyperplastic nodules or adenomas;
(iii) HTs with focal atypical or suspicious areas: this cluster
includes those HTs in which microscopic lesions of dubious
interpretation were detected. These suspicious areas consisted of
thyrocytes arranged in follicles or in solid cell nests, showing
the nuclear features of PTC (nuclear clearing and groves) but
without any evidence of malignancy. Such suspicious thyroid
cells were mostly intimately associated with reactive lymphoid
nodules, or were placed in the context of sclerotic areas; (iv)
HTs with unequivocal microscopic foci of thyroid cancer: when
focal or occult thyroid malignancies were discovered in HTs. Most
of the detected microcarcinomas showed features of PTC with size
less then 4mm in diameter. In isolated cases, follicular variants of
PTC were detected. Both the original diagnosis and subclassifica-
tion of HTs were confirmed by at least two independent
pathologists.
Monoclonal antibodies and immunochemical assay
Formalin-fixed and paraffin-embedded tissue specimens were
used to prepare seriate tissue sections for conventional morpho-
logic analysis as well as for phenotypic and molecular studies.
Purified rat monoclonal antibody (mAb) to galectin-3 (Mabtech,
Nacka, Sweden), mouse mAbs to cyclin D1 (Novocastra Labora-
tories Ltd, Newcastle upon Tyne, UK), mAbs to HBME-1 and to c-
met protein (Dako Corporation, Carpinteria, CA, USA) were used
in immunohistochemistry according to the manufacturer’s in-
structions.
Antigen-retrieval microwave treatment of tissues slides in
0.01moll
 1 citrate buffer pH 6,0 was applied as required. To
minimise the occurrence of false positive results, a biotin-free
immunoperoxidase staining method was considered in this study.
This was obtained by using horseradish-peroxidase conjugated
(HRP-conjugated) rabbit anti-mouse and rabbit anti-rat immu-
noglobulins as secondary antibodies, in indirect immunoperox-
idase assay (Dako).
Briefly, slides were incubated overnight with selected mono-
clonal antibodies at 41C in a moist chamber. Purified rat mAb
directed to galectin-3 was used at a concentration range of 5–
10mgml
 1. Mouse mAbs to c-met protein, HBME-1 and cyclin-D1
were used diluted 1 in 20 to 1 in 50, depending on the antibody
concentration in the batch. After incubation with the appropriate
HRP-conjugated secondary antiserum, the enzymatic activity was
visualised with 3,30-diamino-benzidine (Dako). Finally, slides were
counterstained with Mayer’s haematoxylin and mounted in Eukitt
(Bioptica, Milan, Italy) for microscopy.
Positive cases were classified as þ/  when a weak and
heterogeneous immunostaining was restricted to isolated follicular
cells or cell clusters; and þ when a homogeneous staining of all
the lesion was visible. Immunohistochemical evaluations were
carried out independently by two experienced pathologists.
Laser capture microdissection and loss of heterozygosity
(LOH) analysis
Loss of heterozygosity analysis at 7q32–34 was carried out
focusing on the cluster of HTs with morphologically suspicious
galectin-3-positive areas.
Seriate tissue sections were obtained from a total of 10 HTs and
were subjected to laser microdissection and molecular analysis
with the aim to detect specific genetic alterations. Two cases of
classical HTs (galectin-3 negative) were used as control. In these
cases, apparently normal follicles surrounded by a diffuse
lymphocyte infiltrate were microdissected. In all the other
instances, galectin-3-positive focal undefined lesions or unequi-
vocal thyroid microcarcinomas were specifically microdissected.
Selection and isolation of the candidate cells and/or microscopic
areas to be captured was performed under direct microscopic
visualisation, by using the Pix Cell II Laser Capture Microscope
(Arcturus Engineering, Mountain View, CA, USA). Approximately
500 cells were captured from each lesion and collected onto a
dedicated cap. All caps were handled with gloves to reduce
contamination and kept separately from the others during all the
following experimental procedures. After microdissection and
DNA extraction, polymerase chain reaction (PCR) was carried out
in the presence of specific primers flanking the sequence of two
microsatellite markers (D7S-1779 and D7S-2468) located at the
chromosomal region 7q32–34 (cytogenetic localization 150–
152cM) previously reported to be altered in thyroid cancer (Zhang
et al, 1998; Roque et al, 2001).
Amplification of the microsatellite markers was obtained with
the following primers: D7S-1779-Forward 50-ACCGTGAATACGC
CAAACT-30, D7S-1779-Reverse 50-AGAAGATTCAAAAGTGAAG
AGTTACA-30; D7S-2468-Forward 50-TTTCACAAGAGGCCACCTT
C-30, and D7S-2468-Reverse 50-CGCACCTTACCAATGTGACTT-30.
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performed by means of the hot start technique in a 20ml reaction
mixture containing 200mM dNTP mix, 0.6mM primers, and PCR
reaction buffer (containing 1.25mM MgCl2). Polymerase chain
reaction amplifications were run in the Thermal Cycler PCR
GeneAmp System 2400 (Perkin Elmer Corp., Norwalk, CT, USA).
The reactions consisted in an initial denaturation step at 941C for
5min at the end of which 1U of Taq polymerase (Perkin–Elmer
Corp., Norwalk, CT, USA) was added, followed by 35–40 cycles.
Each cycle was composed of a denaturation step at 941C for 30s, an
annealing step at the requested temperature for 30s, and an
extension step at 721C for 30s. The last cycle was followed by 5-
min incubation step at 721C. Annealing temperature was
determined empirically after an initial estimate based on primer
length and composition. Loss of heterozygosity was analysed by
polyacrylamide gel electrophoresis (PAGE) analysis. Amplified
DNA was mixed with an equal volume of formamide loading dye
(95% formamide, 20mM EDTA, 0.05% bromophenol blue and
0.05% xylen cyanol), and loaded onto a gel consisting of 10–12%
acrylamide (19:1 acrylamide:bisacrylamide), 0.089 M Tris (pH
8,3), 0.089 M borate and 0.002 M EDTA.
Samples were electrophoresed at 150volts for 2–4h, and the
results were visualised by silver staining, using the Silver Stain kit
(Bio-Rad Lab., Hercules, CA, USA). Loss of heterozygosity were
visualised by using an optical densitometry scanner. For
informative cases, the criteria for LOH were complete or near
complete loss of one or both alleles of the DNA band correspond-
ing to the microsatellite sequence. In particular, LOH was defined
according to the following formula: LOH index¼(T2/T1)/(G2/G1),
where T was the suspicious or malignant sample, G was the
matching goiter sample, 1 and 2 were the intensities of smaller and
larger alleles, respectively. Loss of heterozygosity was considered
positive in presence of values of LOH index o0.6 or 41.7.
Reproducibility of each LOH was confirmed by at least two
independent experiments. Constitutional homozigosity was con-
sidered as noninformative. Experiments in which allelic imbal-
ances were detected were repeated twice. Results were reproducible
in all the experiments carried out.
This study has been carried out according to the ethical
guidelines of the Declaration of Helsinki. Specific authorisation
was also obtained by each Institutional Scientific Board.
RESULTS
Presence of transformed thyrocytes and deregulated cell
growth in a subset of HT
In order to investigate the presence of potentially transformed
thyrocytes in HT, an extensive galectin-3 expression analysis has
been done. The results of this study are shown in Table 1.
As expected, galectin-3 was scantily detected in the cluster of the
so called ‘classic HTs’. In these lesions, a focal expression of
galectin-3 was observed in 19% of the instances but it
was restricted to isolated and apparently normal thyroid follicles,
most of which showing oncocytic changes. Interestingly, some of
these follicles were intimately associated to activated lymphoid
nodules in the context of thyroid parenchyma, suggesting the
possibility that such oncocytic cells may trigger a specific immune
response.
In the group of HTs associated to benign proliferating
lesions, galectin-3 was expressed in two oncocytic adenomas. In
isolated instances, this marker was variably detected on scattered
oncocytic follicles also. Hyperplastic thyroid parenchyma and
residual normal parenchyma did not show any galectin-3
immunoreactivity.
Surprisingly, in the cluster of HTs in which focal undefined/
suspicious areas were morphologically detected, galectin-3 im-
munostaining was restricted to such suspicious epithelial struc-
tures. More then 56% of these lesions were highlighted by mAb to
galectin-3, whereas the residual thyroid parenchyma was invari-
ably galectin-3 negative (Table 1 and Figure 1A–D).
As expected, all of the thyroid microcarcinomas discovered in
the context of HT showed a homogeneous galectin-3 expression
(Table 1 and Figure 1E–F).
Occult PTC represented the majority of these malignancies, with
size ranging from 1–4mm. In few instances, aspects of follicular
differentiation were visible. Finally, none of the five unspecific
chronic thyroiditis showed expression of galectin-3 (data not
shown).
To better define the significance of the galectin-3-positive focal
suspicious/atypical lesions detected in HTs, a comparative
expression analysis has been crried out, considering different
molecules that are known to be involved in thyroid cancer and cell
cycle derangement. Results of this analysis are shown in Table 2.
Cases labelled 72–74, representative of classic autoimmune HTs,
were used as negative controls. Interestingly, the expression of
galectin-3 in the aforementioned suspicious/atypical microscopic
areas strongly correlated with the expression of HBME-1, a thyroid
cancer-associated antigen.
Moreover in five out of 12 cases (42%), a sharp nuclear staining
for cyclin D1 was also detected, demonstrating the presence in
these instances of both thyrocytes transformation and deregulated
cell cycle control (Figure 2A–F).
Expression of c-met protein, which is generally observed in
well-differentiated PTC, partially correlated with the expression
of galectin-3 and HBME-1 (66% of the cases). Expression of
c-met protein was also observed in some follicles showing
oncocytic features without any morphological evidence of
malignancy. These follicular structures were found associated to
infiltrating lymphocytes or in the context of activated lymphocyte
nodules.
The significance of this finding, observed in some instances in
galectin-3 immunostaining also, is under investigation.
As expected, almost all the thyroid papillary carcinomas tested
as controls showed coexpression of galectin-3, HBME-1, c-met
protein and cyclin D1 (data not shown). A PTC case was included
in Table 2 as positive control.
All together these findings suggest that specific subsets of HTs
may harbour potential thyroid cancer’s precursors.
Loss of heterozygosity at specific chromosomal loci in
Hashimoto’s thyroiditis
Specific allelic loss for microsatellite D7S-2468 was demonstrated
in three out of three focal undefined lesions (FULs) associated to
HTs and in four out of six foci of micro-PTCs discovered in such
diseases, by using laser capture microdissection followed by DNA
extraction and PCR. Two cases of classical HTs were used as
negative controls (Figure 3 and data not shown). All the HTs cases
considered in this analysis were previously assessed for expression
of galectin-3.
Polymerase chain reactions were carried out in the presence of
specific primers flanking the sequence of two microsatellite
markers D7S-1779 and D7S-2468 located at the chromosomal
region 7q32–34 (see Material and methods section for detail). Loss
of heterozygosity for the specific microsatellite region was
restricted to galectin-3-positive thyrocytes microdissected from
the aforementioned suspicious or malignant areas, while thyroid
cells isolated from the surrounding galectin-3-negative parenchy-
ma, as well as from the thyroid follicles of classic HTs, retained
heterozygosity (Figure 3).
These findings indicated that loss of genetic material, and in
particular LOH at a critical region of the long arm of chromosome
7 (7q32–34) was associated to both morphologic and phenotypic
alterations of thyrocytes.
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evaluated immunohistochemically by using a biotin-free detection system
Case no. Galectin-3 expression
HTs with classic morphologic features of chronic autoimmune thyroiditis
1 + Focal area with oncocytic cells
2 Neg.
3 Neg.
4 Neg.
5 Neg.
6 7 Focal area with oncocytic cells
7 7 Focal area with oncocytic cells
8 Neg.
9 Neg.
10 Neg.
11 Neg.
12 Neg.
13 Neg .
14 Neg.
15 Neg.
16 Neg.
17 Neg.
18 Neg.
19 Neg.
20 + Oncocytic cells associated to lymphatic nodule
21 Neg.
22 + Focal area with oncocytic cells
23 Neg.
24 Neg.
25 + Scattered follicles
26 + Scattered follicles, some with oncocytic features
27 Neg.
28 Neg.
29 Neg.
30 Neg.
31 Neg.
32 Neg.
33 Neg.
34 Neg.
35 + Scattered follicles
36 + Solid cell nests
37 + Scattered follicles
38 Neg.
39 Neg.
40 Neg.
41 Neg.
42 Neg.
43 Neg.
44 Neg.
45 Neg.
46 Neg.
47 Neg.
48 Neg.
49 7 Weak and focal staining of some oncocytic follicles
50 Neg.
51 Neg.
52 Neg.
53 Neg.
54 Neg.
55 Neg.
56 Neg.
57 Neg.
58 Neg.
59 Neg.
60 Neg.
61 Neg.
62 Neg
63 Neg.
64 + Oncocytic cells associated to lymphatic nodule
65 Neg.
66 7 Focal area with follicular structures and tall cells
67 Neg.
68 7 Focal area with follicular structures and tall cells
69 Neg.
70 Neg.
71 Neg.
72 Neg.
73 Neg.
74 Neg.
75 Neg.
76 Neg.
77 Neg.
78 Neg.
79 Neg.
80 Neg.
81 + Scattered oncocytic follicles
82 + Scattered oncocytic follicles
83 + Oncocytic follicles associated to lymphatic nodule
84 Neg.
85 Neg.
86 Neg.
87 Neg.
HTs associated to hyperplastic/adenomatous lesions
88 7 Weak staining of scattered oncocytic follicles
90 7 Weak staining of oncocytic adenoma
91 Neg.
92 Neg.
93 + Oncocytic adenoma, solid cell nests and atypical oncocytic follicles
associated to lymphatic nodules
a
94 Neg.
95 Neg.
96 Neg.
97 Neg.
HTs with focal undefined/suspicious thyroid lesions
98 + Follicles with clear nuclei and isolated nuclear groves
100 Neg. (atypical follicles)
101 + Focal area with atypical follicles fibrosis and sclerosis
102 + Scattered suspicious follicles
103 Neg. (follicles with clear nuclei)
104 + Focal area with atypical follicles
105 Neg. (atypical follicles)
106 + Solid cell nests and follicles associated with lymphatic nodule
107 Neg. (follicles with clear nuclei)
108 Neg. (follicles with clear nuclei)
109 Neg. (suspicious oncocytic lesion)
110 + Suspicious follicles with tall cells associated to lymphatic nodules e
scattered oncocytic follicles
111 + Microscopic area with atypical follicles, fibrosis and sclerosis
112 + Solid cell nests
113 Neg. (suspicious oncocytic follicles)
HTs associated to thyroid malignancies
114 + Microcarcinoma PTC
116 + Microcarcinoma PTC-follicular variant
117 + Microcarcinoma PTC
118 + Microcarcinoma PTC-follicular variant
119 + Microcarcinoma PTC
120 + Microcarcinoma PTC
121 + Microcarcinoma PTC
122 + Microcarcinoma PTC and some scattered follicles
123 + Microcarcinoma PTC
124 + Microcarcinoma PTC
125 + Microcarcinoma oncocytic type
126 + Microcarcinoma PTC
127 + Microcarcinoma PTC-follicular variant and atypical follicles in sclerosis
128 + Atypical follicles with clear nuclei and oncocytic follicles associated to
lymphatic nodules
129 + Microcarcinoma PTC
130 + Microcarcinoma PTC
131 + Microcarcinoma PTC
132 + Microcarcinoma PTC
133 + Microcarcinoma PTC
aAtypical follicles are defined as thyroid follicles showing nuclear changes (clear nuclei with
or without groves), which are generally observed in papillary thyroid carcinomas (PTC).
Table 1 (Continued)
Case no. Galectin-3 expression
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yFigure 1 Galectin-3 expression in a subset of HTs showing focal suspicious follicular structures. Galectin-3-positive atypical thyrocytes, organized in
follicles, are intimately associated to a lymphoid nodule (A) or localised within sclerotic areas (B). A single galectin-3-positive atypical thyroid follicle with tall
cells. A mitosis is clearly visible in the center of the follicle (inset) (C). A classic type of HT was used as negative control (D). (E–F) Atypical galectin-3-
positive follicular structures, suggestive of microcarcinomas (scale bar A:4 3mm; B, D, F:5 5mm; C, E: 27.5mm).
Table 2 Comparative expression of galectin-3, c-met protein, HBME-1 and cyclin D1 in a subset of HTs harbouring undefined microscopic lesions
Case no GAL-3 c-met HBME-1
Cyclin-D1
(nuclear
staining)
72 (neg. control) Neg. + Oncocytic follicles Neg. Neg.
73 (neg. control) Neg. + Oncocytic follicles Neg. Neg.
74 (neg. control) Neg. + Oncocytic follicles Neg. Neg.
26
a + Oncocytic follicles + Oncocytic follicles + Oncocytic follicles + Oncocytic
follicles
35 Neg. Neg.
+ Apparently normal follicles + Some oncocytic follicles + Apparently normal follicles
68 Neg. Neg.
7 Suspected follicles with tall cells + Some oncocytic follicles 7 Suspected follicles with tall cells
83 + Suspected minimal oncocytic lesion + Suspected minimal oncocytic lesion and
other oncocytic follicles
+ Suspected minimal oncocytic
lesion
Neg.
93
a + Atypical area and some oncocytic follicles + Atypical area and some oncocytic follicles + Atypical area + Atypical area
98 + Atypical follicles 7 Atypical follicles and some oncocytic
follicles
+ Atypical follicles Neg.
101 + Atypical follicles in sclerosis + Atypical follicles in sclerosis and some
oncocytic follicles
+ Atypical follicles in sclerosis Neg.
102
a + Atypical follicles + Atypical follicles and some oncocytic
follicles
+ Atypical follicles + Atypical follicles
104 + Suspected atypical follicles Neg. + Suspected atypical follicles Neg.
106
a + Atypical follicles + Atypical follicles and some oncocytic
follicles
+ Atypical follicles + Atypical follicles
110 Neg.
+ Suspected atypical follicles + Some oncocytic follicles + Suspected atypical follicles NE
b
111
a + Atypical follicles and some oncocytic
follicles
7 Atypical follicles and some oncocytic
follicles
+ Atypical follicles + Atypical follicles
PTC as positive
control
+ PTC + PTC and some peritumoral follicles + PTC + PTC
aThese lesions showing coexpression of markers associated to transformed thyroid cells and deregulated cell cycle control may be considered as precursors of thyroid cancer.
bNE¼not evaluated.
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findings suggest that at least some of the FULs observed in HTs
may likely represent thyroid cancer’s precursors.
DISCUSSION
The pathogenetic variability of HT
Many immunological and genetic studies have been carried out in
order to elucidate the pathophysiology of HT. Intriguing experi-
mental evidences from two independent groups suggested that
apoptosis may be responsible for the thyroid cells destruction
observed in HT (Giordano et al, 1997; Hammond et al, 1997; Stassi
and De Maria, 2002). The proposed mechanism involves Fas, a
member of the tumour necrosis factor receptor family. Cross-
linking of Fas with its specific ligand (FasL) is sufficient to induce
apoptosis in the Fas-bearing cells. Although Fas is mainly
expressed on activated T lymphocytes and natural killer cells,
which are the effectors of the immunoresponse against viruses and
tumours, follicular thyroid cells in HT have been also found to
express Fas on their cell surface. Fas expression is induced by IL-
1b, a cytokine produced by activated lymphocytes. Fas-positive
target thyrocytes are killed when exposed to FasL-positive
neighbouring thyroid cells. Although Fas–FasL-mediated apopto-
sis in thyrocytes is probably not so simple as originally conceived,
this mechanism may likely explain the determinism of thyroid
atrophy and hypothyroidism observed in a subset of HTs (Dayan
et al, 1997; Mirakian et al, 1998). However, from the immunolo-
gical point of view, other mechanisms could be involved in the
Figure 2 Comparative expression of galectin-3, HBME-1 and cyclin D1 in selected focal suspicious lesions detected in HTs. (A–C) Expression of galectin-
3, HBME-1 and cyclin D1 in a single atypical follicle detected in HT. Galectin-3 staining is restricted to the cytoplasm of follicular cells (A), whereas HBME-1 is
expressed on the plasma membrane with incomplete latero-lateral and apical staining pattern (B). On the other hand, specific cyclin D1 nuclear staining is
visible in about 50% of the nuclei (C). (D–F) In this case, the suspicious lesion is represented by atypical follicles surrounded by intense lymphocyte
infiltration. Galectin-3 is variably expressed in this lesion with a cytoplasm pattern of staining (D). Coexpression of HBME-1 (E) and cyclin D1 (F) is also
visible (scale bar A–C:2 5mm; D:4 3mm; E–F:5 5mm).
Figure 3 Laser capture microdissection (LCM) and of LOH for
microsatellite D7S-2468 in a focal galectin-3-positive undefined lesion
(FUL) detected in HT. The upper panel shows a classic case of HT and a
focal undefined lesion detected in HT before and after laser microdissec-
tion. Note that galectin-3 expression was restricted to the FUL (dark
staining). The black line outlines the microdissected areas. The lower panel
shows an LOH for microsatellite D7S-2468 in the galectin-3-positive lesion.
(scale bar HT: 43mm; FUL: 55mm).
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recognition of self-antigens by activated CD4þ (helper) T
lymphocytes. In this context, HT may be triggered by at least
three different mechanisms. The first, referred as ‘molecular
mimicry’, is supported by the serological evidence of bacterial or
viral infection in patients with HT.
A common epitope of an infectious antigen, similar to a thyroid
protein, could results in activation of specific T lymphocytes
(Davies et al, 1991; Zhao et al, 1998).
An alternative mechanism implies the loss of self-tolerance that
may result from defective deletion or anergy of specific T
lymphocytes, targeted against self-antigens. Similar effects may
be generated by loss of suppression of self-reactive T cells by
regulatory cells secreting immunosuppressive cytokines (Walker
and Abbas, 2002). A third mechanism of cell injury is based on the
assumption that thyroid cells may present their own intracellular
proteins to CD4þ T lymphocytes. This view is supported by the
finding that thyroid cells during thyroiditis may express the major
histocompatibility complex (MHC) class II proteins, a critical
structure for antigen presentation to CD4þ T lymphocytes.
Furthermore, interferon-g released from activated T lymphocytes
can induce the expression of MHC class II molecules on thyroid
cells, leading T-cell restimulation and perpetuation of the
autoimmune process (Huang and Kukes, 1999). Once activated,
self-reactive CD4þ T lymphocytes can stimulate autoreactive B
cells to secrete thyroid autoantibodies, among which those
directed to thyroglobulin (TG), thyroperoxidase (TPO) and
thyrotropin receptor (TSHr) are better known. Together with the
possibility that thyroid cells can present self-antigens to CD4þ T
lymphocytes, it should be considered that mutational events
inducing thyrocytes transformation may potentially drive the
expression of aberrant proteins on the cell surface (Powell et al,
2003). This mechanism represents per se a condition that is
necessary and sufficient for triggering an active immunological
response to still undefined neoexpressed antigens. The Chernobyl’s
disaster strongly supports this possibility. Pacini et al (1998)
reported that post-Chernobyl Belarus thyroid carcinomas were
frequently associated with ‘thyroid autoimmunity’. Thyroid
lymphocyte infiltration and circulating anti-TPO antibodies, in
fact, were consistently detected in Belarus patients with respect to
the controls (Pacini et al, 1998). Moreover, oncocytic changes of
thyroid cells have been reported among the late chronic thyroid
alterations observed after Chernobyl disaster, with a frequency
ranging from 17 to 42% (Nikiforov and Gnepp, 1999). These
clinical-pathological pictures of chronic autoimmune thyroiditis
are very similar to those observed in HT.
It is intriguing to speculate that in these thyroid conditions, a
specific immune response to still undefined aberrant proteins may
be induced by radiation damages. This interpretation is fully in
line with the observation of both autoimmune thyroiditis and
increased risk of thyroid cancer in survivors of the atomic bomb
blast, as well as in subjects exposed to radiation fallout in the
Marshall Islands (Nagataki et al, 1994). These human tragedies
provide per se an unequivocal demonstration that a subset of
chronic autoimmune thyroiditis (with histological features of HTs)
may harbour transformed thyrocytes and can be triggered by a
qualitatively different immune response. Although these facts can
explain at least in part the origin of HTs, we should consider that
the aforementioned pathogenetic mechanisms are sustainable also.
For these reasons, we believe that HTs should be considered more
properly as a spectrum of different thyroid conditions rather than
as a single and well-defined clinical–pathological entity.
Hashimoto’s thyroiditis may harbour potential precursor
lesions of thyroid cancer
The morphological and phenotypic analysis reported here
provides the evidence that a subset of HTs may harbour potential
thyroid cancer’s precursors. This concept is substantiated by the
finding that a gradient of expression of galectin-3, a well-know
molecule associated to thyrocytes transformation, has been
observed in different clusters of morphologically categorised
HTs. Interestingly, the most relevant expression of galectin-3 was
specifically detected in those HTs harbouring focal suspicious
areas, as well as in almost all microcarcinomas discovered in HT
(Bartolazzi et al, 2001; Takenaka et al, 2003; Yang and Liu, 2003).
Classic chronic
autoimmune
HT
HT with
focal undefined lesions
(precursor lesions) 
and/or 
 microcarcinoma
HT with benign
proliferative lesions
Molecular mimicry
Loss of T- cell tolerance 
Fas−FasL interaction 
Direct presentation of self-antigens  
Increased TSH levels and other 
proliferative stimuli
Possible superimposed low-grade 
molecular alterations affecting cell cycle 
control and thyrocytes morphology
High-grade molecular alterations 
inducing thyrocytes transformation 
Presence of autoantibodies  Possible presence of autoantibodies and 
specific immuno-response to still undefined 
neoexpressed antigens
Prevalence of immuno-response to 
tumour-associated antigens and/or 
aberrant proteins
Possible coexistence of autoantibodies
Figure 4 Preliminary pathogenetic hypothesis for the different clusters of HTs identified in this study.
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assessed for the comparative expression of HBME-1, c-met protein
and cyclin D1 (Hall and Peters, 1996; Miettinen and Karkkainen,
1996; Ruco et al, 2001).
HBME-1 identifies a monoclonal antibody directed to a
biochemical unknown epitope, which is consistently expressed in
thyroid cancer (Miettinen and Karkkainen, 1996). Both galectin-3
and HBME-1 are commonly used in clinical practice as diagnostic
tools for improving the accuracy of conventional histomorpholo-
gical methods (Miettinen and Karkkainen, 1996; Bartolazzi et al,
2001). On the other hand, overexpression of c-met protein has
been reported as a distinguish feature of well-differentiated
papillary carcinoma (Ruco et al, 2001).
With regard to cyclin D1, it is a well-known regulator of cell
cycle and its overexpression plays an important role in tumour
progression (Hall and Peters, 1996; Wang et al, 2000). Cyclin D1
forms a multimeric complex with cyclin-dependent kinase, which
facilitate transition through the restriction point of cell cycle by
inactivation of the retinoblastoma tumour-suppressor protein
(pRb). Constitutive overexpression of cyclin D1, caused by
chromosomal abnormalities, gene amplification or other post-
translational mechanisms has been reported in different types of
tumours including thyroid cancer (Hall and Peters, 1996; Wang
et al, 2000). For these reasons, the concurrent expression of
galectin-3, HBME-1, c-met protein and cyclin D1 observed in some
suspicious lesions in the context of HTs strongly suggests the
presence of transformed thyrocytes.
Genetic and exogenous factors have also been involved in the
determinism of HT. It is noteworthy that proliferative lesions
associated with HT, but not the perilesional tissue involved by the
inflammatory infiltration, may be karyotypically abnormal (Vanni
et al, 2000). This means that cytogenetic changes are likely due to
the derangement of the cell cycle regulatory machinery rather than
to the inflammatory parenchymal alterations. Although the
detection of molecular alterations in HT, such as the presence of
the papillary carcinoma-related fusion gene RET/PTC, is still a
matter of discussion, the loss of genetic material at specific
chromosomal loci has been demonstrated by Hunt and co-workers
(Wirtschafter et al, 1997; Hunt et al, 2002; Nikiforova et al,
2002). We show here that LOH for a microsatellite located in the
chromosomal region 7q32–34, previously reported in PTC,
also occurs in some galectin-3-positive focal undefined lesions
detected in HTs. Although further investigations are necessary to
better clarify the biological significance of these findings,
the phenotypical and molecular alterations reported here
strongly suggest the presence of thyroid cancer precursors
in a subset of HTs. If it is true that the clinical impact of early
detection of thyroid cancer precursors and/or occult thyroid
carcinomas in HTs must be demonstrated and will be matter of
discussions, it is unquestionable that the concept of ‘Hashimoto’s
thyroiditis’ as a single clinical–pathologic entity should be
revisited. The subclassification of HTs that we propose provides
the basis for further clinical, pathological and molecular investiga-
tions aimed to better understand the clinical outcome and to
improve the management of these heterogeneous thyroid condi-
tions.
A preliminary attempt to establish a pathophysiological model,
which can explain, at least in part, the spectrum of the thyroid
conditions that we observed is shown in Figure 4. Further
experimental and clinical investigations will certainly contribute
to better understand when HT will progress towards a complete
atrophy of thyroid parenchyma and hypothyroidism, when
tumours will arise and when a chronic autoimmune thyroiditis
will be indolent over the years.
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